European Leveraged Finance & CLO Summit

Is liquidity masking credit quality?

20 - 22 April 2021

Pharma & Healthcare

M&A, COVID-19 and other social risks to drive credit quality

  • Pharmaceuticals: Which segments will take longer to recover patient volumes and will be more prone to M&A?
  • Medical Devices: What is the shape of the recovery in medical devices? What are the key downside risks to a sustainable rebound?
  • Laboratories: How long will the tailwind from COVID-19 testing last for? What will be the credit impact of M&A resumption?
  • Healthcare facilities: What is the outlook beyond government support? Expectations regarding M&A and regulation

Loading feed

share